Eurofins Scientific SE (EPA: ERF)

France flag France · Delayed Price · Currency is EUR
51.64
-0.04 (-0.08%)
Aug 30, 2024, 5:37 PM CET
-8.50%
Market Cap 9.88B
Revenue (ttm) 6.72B
Net Income (ttm) 325.90M
Shares Out 191.37M
EPS (ttm) 1.67
PE Ratio 30.96
Forward PE 14.92
Dividend 0.50 (0.97%)
Ex-Dividend Date Jul 3, 2024
Volume 909,343
Open 51.08
Previous Close 51.68
Day's Range 51.06 - 52.18
52-Week Range 39.47 - 62.10
Beta 0.67
Analysts n/a
Price Target n/a
Earnings Date Oct 18, 2024

About Eurofins Scientific SE

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of various analytical methods and tests to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, a... [Read more]

Sector Healthcare
Founded 1987
Employees 61,798
Stock Exchange Euronext Paris
Ticker Symbol ERF
Full Company Profile

Financial Performance

Financial Statements

News

Eurofins Scientific announces the acquisition of Labormar, further expanding its presence in Latin America and its Food and Feed, Environmental, Cosmetic and Pharmacological testing offering in Colombia

BARRANQUILLA, Colombia--(BUSINESS WIRE)--The Eurofins network of companies, a world leader in food, environment, pharmaceutical and cosmetic product testing, announces the completion of the acquisitio...

7 weeks ago - Business Wire

Eurofins Scientific's stock drops on allegations from short-seller Muddy Waters

Eurofins Scientific shares plunged on Monday after Muddy Waters Research said in a report it had started shorting the laboratory-services company, alleging founder and Chief Executive Gilles Martin ha...

2 months ago - Market Watch

Eurofins Scientific Announces the Acquisition of Quasfar, Establishing a Presence in Colombia and Expanding the Presence of Eurofins Laboratories in Latin America

LUXEMBOURG--(BUSINESS WIRE)--The Eurofins network of companies, the global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced m...

10 months ago - Business Wire

Eurofins Scientific Announces the Acquisition of Labor 3, Further Expanding Its Offering to the Food and Feed Market in Brazil and the Presence of Eurofins Laboratories in Latin America

LUXEMBOURG--(BUSINESS WIRE)--The Eurofins network of companies, the global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced m...

10 months ago - Business Wire

Eurofins and Rite Aid Launch an Over-the-Counter, FDA-Authorised, at-Home COVID-19 PCR Test in all Rite Aid Locations in the U.S.

LUXEMBOURG--(BUSINESS WIRE)--Eurofins (Paris:ERF), through its empowerDX subsidiary, and Rite Aid announce the launch of an over-the-counter, FDA-authorised[1], at-home COVID-19 PCR Test Kit. The co-b...

3 years ago - Business Wire

TruGraf Contracted With Humana for In-network Coverage of Medicare Kidney Transplant Patients

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Transplant Genomics, Inc. (“TGI”), the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide, is excited to announce...

3 years ago - Business Wire

Eurofins Subsidiary empowerDX and Uber Team up, Offer At-home COVID-19 Testing Kits via On-demand Delivery in More Than Two Dozen U.S. Cities

LUXEMBOURG--(BUSINESS WIRE)--Eurofins subsidiary, empowerDX, is working with Uber to offer FDA-emergency use authorized, at-home COVID-19 testing kits to consumers.

3 years ago - Business Wire

The Tell: Here are the top ‘high-conviction' buys for Q3 from star stock-pickers according to Morningstar

Research provider Morningstar is out with its list of the 10 most “high-conviction” purchases among “ultimate stock pickers,” and the results are a bit eclectic.

4 years ago - Market Watch